Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testingCommentary Published on 2021-07-012022-10-29 Journal: Translational Medicine Communications [Category] COVID-19, [키워드] antibody complicate cross-reactive antibodies de novo Epidemiology exhibited healthy individuals identify immune response Inclusion individual limitations Neutralizing activity nucleocapsid protein observation overcome pandemic positive potential limitation progressed PROTECT RBD receiving recent reported Research RT-PCR SARS-CoV-2 SARS-COV-2 infection sera serological test Serological testing Spike protein tested therapy Topic Treatment Vaccine virus while [DOI] 10.1186/s41231-021-00093-2 PMC 바로가기 [Article Type] Commentary
Seroprevalence of SARS-CoV-2 infection among pet animals in Croatia and potential public health impact크로아티아의 애완 동물 사이에서 SARS-CoV-2 감염의 혈청 유병률 및 잠재적인 공중 보건 영향Article Published on 2021-07-012022-09-12 Journal: Transboundary and emerging diseases [Category] SARS, 진단, [키워드] acute respiratory syndrome antibodies antibody cats caused China collected Contact coronavirus COVID-19 Croatia dogs ELISA enzyme-linked immunosorbent Epidemiology Europe faculty global pandemic Health Service Human human sera Infection Laboratory Medicine microneutralisation test MNT neutralising antibody Neutralizing positive practitioners public health Randomly reactivity risk SARS-CoV-2 SARS-COV-2 infection selected sera Seroepidemiologic studies seropositive Seroprevalence Serosurvey serum sample serum samples susceptibility tested titre Total university was recorded [DOI] 10.1111/tbed.13924 PMC 바로가기 [Article Type] Article
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel이스라엘, 의료 종사자의 Comirnaty(BNT162b2, BioNTech/Pfizer) 백신 접종 후 Delta(B.1.617.2) 및 기타 우려 변종에 대한 중화 능력Rapid Communication Published on 2021-07-012022-09-10 Journal: Eurosurveillance [Category] SARS, 변종, [키워드] Alpha B.1.1.7 B.1.351 B.1.617.2 B.1.617.2 (Delta) Beta BNT162b2 BNT162b2 vaccination COVID-19 Delta demonstrated Europe female Fold change Gamma health care workers healthcare worker neutralisation neutralising Neutralizing not significant other variant P.1 Protective reduction reduction in SARS-CoV-2 SARS-CoV-2 delta sera titre vaccination variant variants VoC [DOI] 10.2807/1560-7917.ES.2021.26.26.2100557 PMC 바로가기 [Article Type] Rapid Communication
Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers의료 종사자들 사이에서 ChAdOx1 nCoV-19 백신의 첫 번째 접종 전후의 5가지 SARS-CoV-2 항체 분석 결과 비교Immunoassays Published on 2021-06-302022-09-12 Journal: Journal of Clinical Microbiology [Category] MERS, SARS, 진단, [키워드] Abbott acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse reaction Adverse reactions All participants antibody Antibody assays Antibody titer Antibody titers applied assay assays AstraZeneca AZ vaccine baseline ChAdOx1 nCoV-19 conducted contribute coronavirus correlation correlations Cutoff Day Efficacy Factor first dose FIVE Genscript help Laboratory Participants questionnaire Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SD Biosensor sera serum sample serum samples severe acute respiratory syndrome Coronavirus severe adverse reactions severity Siemen significantly higher single dose Spread Symptoms tested titer vaccination Vaccine Virus neutralization worker [DOI] 10.1128/JCM.01105-21 PMC 바로가기 [Article Type] Immunoassays
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative AssaysSARS-CoV-2 항체 수준을 결정하기 위한 스파이크 방지 단백질 분석: 5가지 정량 분석의 일대일 비교Research Article Published on 2021-06-302022-09-12 Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, [키워드] Abbott acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-SARS-CoV-2 antibody Anti-spike antibodies antibody Antibody assays Antibody Response assay standardization assays BAU binding antibody binding antibody unit binding antibody units BNT162b2 calculated comparison coronavirus correlation DiaSorin eliminated evaluated FIVE highlight IgG immunization Immunoglobulin individual International international standard magnitude milliliter neutralization test of BNT162b2 Pfizer/BioNTech quantification Quantitative quantitative antibody assays Quantitative assays quantitative methods Result Roche S1/S2 SARS-CoV-2 sera serology severe acute respiratory syndrome Coronavirus significantly lower single dose Spike protein Standardization suggested surrogate virus neutralization test sVNT tested the antibody response the WHO trimeric spike vaccination Vaccine Vaccine failure viral spike protein virus neutralization test [DOI] 10.1128/Spectrum.00247-21 PMC 바로가기 [Article Type] Research Article
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infectionmRNA-1273 백신 접종에 의해 유도된 항체는 SARS-CoV-2 감염에서보다 수용체 결합 도메인에 더 광범위하게 결합합니다Research Article Published on 2021-06-302022-09-10 Journal: Science Translational Medicine [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immunity affected antibodies antibody antibody epitope antibody epitopes antibody immunity Antibody Response Antibody responses antigenic evolution binding breadth characterized convalescent sera coronavirus deep demonstrated dose elicited epitope Epitopes erosion greater human antibody response Immunity immunization Infection less Moderna mRNA-1273 vaccine mRNA mRNA-1273 mRNA-1273 COVID-19 vaccine Mutation natural infection neutralization Neutralizing activity Neutralizing antibodies neutralizing antibody polyclonal antibodies polyclonal antibody raised RBD RBD mutation RBD-binding antibody Receptor binding domain Receptor-binding domain respiratory SARS-CoV-2 SARS-CoV-2 evolution SARS-COV-2 infection SARS-CoV-2 spike protein sera severe acute respiratory syndrome Coronavirus specificity Spike protein susceptibility the antibody response the RBD the receptor-binding domain the SARS-CoV-2 vaccination Vaccine variant variants Viral viral evolution viral mutation Viral mutations [DOI] 10.1126/scitranslmed.abi9915 PMC 바로가기 [Article Type] Research Article
High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infectionMethod Article Published on 2021-06-292022-10-04 Journal: MethodsX [Category] 치료기술, [키워드] Abstract affinity Affinity maturation Analysis anti-RBD antibody Antibody binding antibody isotypes antibody profiling binding biosensor Concentration Corona Course determine healthy individual high throughput IgA IgA antibody IgA level IgG IgG level IgM Image immune reaction Immune status Immunoglobulin individual Infection Infectious diseases isotype measure mutant Off-rate Patient patients performed Plasmon polyclonal provide RBD recovered resonance SARS-CoV-2 Screening sera shown SPR surface the disease the RBD the RBD protein turn vaccination was used [DOI] 10.1016/j.mex.2021.101432 PMC 바로가기 [Article Type] Method Article
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variantsCOVID-19 mRNA 백신 유도된 3가지 SARS-CoV-2 변이체에 대한 항체 반응Observational Study Published on 2021-06-282022-09-10 Journal: Nature Communications [Category] MERS, SARS, 변종, 임상, 진단, [키워드] Affect antibodies Antibody Response B.1.1.7 B.1.1.7 variant B.1.351 B.1.351 variant BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BNT162b2 vaccine circulating circulating SARS-CoV-2 variants Clinical use COVID-19 COVID-19 patients COVID-19 vaccine cross-neutralization D614G substitution Efficacy Evidence exceeded Health care Health care worker health care workers induce mRNA vaccine Mutation neutralization neutralize Neutralizing antibodies neutralizing antibody not affected protective immunity provide raised Re-infection reduced reduction RNA vaccines SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 second dose sera seronegative vaccinee seronegative vaccinees show specific neutralizing antibodies Spike protein the SARS-CoV-2 the spike protein titre Vaccine vaccine candidate vaccine candidates vaccine efficacy variant [DOI] 10.1038/s41467-021-24285-4 PMC 바로가기 [Article Type] Observational Study
Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets흰 족제비의 INO-4800 백신 접종 후 501Y.V1 및 501Y.V2 SARS-CoV-2 변이체의 살아있는 바이러스 중화Immunology Published on 2021-06-252022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단, [키워드] 501Y.V1 501Y.V2 affecting biomolecular modelling comparable Course COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines DNA vaccine dose effective ferret ferrets immune responses in silico Influenza influenza pandemic INO-4800 investigated less media morbidity and mortality neutralisation neutralisation titre Neutralisation titres Neutralising Antibodies neutralising antibody nucleic acid nucleic acid vaccine Nucleic acid-based vaccines over pandemic PROTECT reported SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 variant SARS-CoV-2 variants sera supported titre titres vaccine-induced immune response Vaccine-induced immunity variant variants virus isolate [DOI] 10.3389/fimmu.2021.694857 PMC 바로가기 [Article Type] Immunology
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or VaccinationArticle Published on 2021-06-252022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-N IgG Anti-RBD IgG anti-S IgG AstraZeneca avidity B.1.1.7 B.1.351 BNT162b2 ChAdOx1 concern contribute convalescent COVID-19 cVNT demonstrated detectable development domain Evidence examined humoral immune response Humoral immunity IgG immune response immunoblot Immunoglobulin increase in Infection Maturity Moderna mRNA-1273 neutralization Pfizer/BioNTech RBD reactivity robust SARS-CoV-2 SARS-COV-2 infection second dose sera Specific starting sVNT tested titer vaccination vaccine dose vaccinee vaccinees variants of concern viral spike virus variants virus-neutralizing antibodies virus-neutralizing antibody VoC was determined were used [DOI] 10.3390/vaccines9070700 PMC 바로가기 [Article Type] Article